A 24-week pegylated interferon alpha-2b versus a 12-week pegylated interferon alpha-2b alone or with ribavirin for patients with acute hepatitis C

摘要

We read with great interest the manuscript by Santantonid et al. reporting on the results of the open, randomized, multicen-ter trial to assess efficacy and safety of a 24-week course of pegy-lated interferon (Peg-IFN) alpha-2b versus a 12-week course of Peg-IFN alone or with ribavirin (RBV) in acute hepatitis C (AHC) patients. With similar rates of sustained virological response (SVR; 70.5%-72.1% and 81.6% by intent-to-treat and per-protocol analysis, respectively), the researchers concluded that Peg-IFN induces a high SVR rate in AHC patients and treatment regimens do not influence the response rate.